These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20164673)

  • 1. [Outlook: Future therapy of renal cell carcinoma].
    Bergmann L; Miller K
    Onkologie; 2010; 33 Suppl 1():18-20. PubMed ID: 20164673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [First-line therapy of metastatic renal cell carcinoma--update 2009].
    Miller K
    Onkologie; 2010; 33 Suppl 1():5-9. PubMed ID: 20164669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal cell carcinoma management and therapies in 2010].
    Albouy B; Gross Goupil M; Escudier B; Massard C
    Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
    Hutson TE
    Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
    Norum J; Nieder C; Kondo M
    J Chemother; 2010 Apr; 22(2):75-82. PubMed ID: 20435564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y
    Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
    Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    Chowdhury S; Larkin JM; Gore ME
    Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
    Ivanyi P; Grünwald V
    Aktuelle Urol; 2015 Nov; 46(6):467-72. PubMed ID: 26556569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
    Bellmunt J; Flodgren P; Roigas J; Oudard S
    BJU Int; 2009 Jul; 104(1):10-8. PubMed ID: 19388982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
    Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
    Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
    Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
    Schmidinger M; Zielinski CC
    Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for metastatic renal cell carcinoma.
    Kroog GS; Motzer RJ
    Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.